gnipst bulletin 22.2
TRANSCRIPT
-
7/29/2019 GNIPST Bulletin 22.2
1/14
1118-1177-4796-9849-7562-5062 mail
GNIPST BULLETIN 2012
25 th January 2013 Volume No.: 22 Issue No.: 02
Contents Message from GNIPST
Letter to the Editor News Update Disease Outbreak News Health Awareness Forth Coming Events Drugs Update Campus News Students Section Editors Note Archive
Vision
TO GROW AS A CENTRE OF EXCELLENCE IN THE FIELD OF
PHARMACEUTICAL AND BIOLOGICAL SCIENCE
EDITOR: Debabrata Ghosh Dastidar
GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE ANDTECHNOLOGY
GNIPST Photo Gallery For your comments/contribution OR
For B ack-Issues , mailto:[email protected]
1
https://picasaweb.google.com/111714720327580099858/Tour2013mailto:[email protected]:[email protected]:[email protected]://picasaweb.google.com/111714720327580099858/Tour2013 -
7/29/2019 GNIPST Bulletin 22.2
2/14
25-01-2013
MESSAGE FROM GNIPST
All the members of GNIPST are proud to publish the 22 nd Volume
of GNIPST BULLETIN. This bulletin has successfully completed
its twenty months journey. We hope it has kept the readers updated
of recent activities in pharmaceutical & biological sciences and also
introduced them with the different activities of our esteemed
institution. We are thankful to all of you for your great cooperation
& support and are looking forward to the samein future.
LETTER TO THE EDITOR .
NEWS UPDATE
'Quadruple Helix' DNA Discovered in Human Cells(20 JANUARY 2013 )
In 1953, Cambridge researchers Watson and Crick published anarticle describing the interweaving "double helix" DNA structure --
the chemical code for all life. Now, in the year of that scientific
landmark's 60th Anniversary, Cambridge researchers have
published another article demonstrating that four-stranded
"quadruple helix" DNA structures -- known as G-quadruplexes --
also exist within the human genome.
One Form of Neuron Turned Into Another in Brain(20 JANUARY 2013 )
Click here to go at the top 1
http://www.sciencedaily.com/releases/2013/01/130120150033.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130120150033.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130120150033.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29 -
7/29/2019 GNIPST Bulletin 22.2
3/14
25-01-2013
A new finding by stem cell biologists turns one of the basics of
neurobiology on its head -- demonstrating that it is possible to turn
one type of already differentiated neuron into another within the
brain.
Regular Aspirin Use Linked to Increased Risk ofAge- Related Macular Degeneration(21 JANUARY 2013 )
Regular aspirin use appears to be associated with an increased riskof neovascular age-related macular degeneration, which is a leading
cause of blindness in older people, and it appears to be independent
of a history of cardiovascular disease and smoking.
New Way to Kill Lymphoma Without Chemo-
therapy: Golden Nanoparticle Starves Cancer
Cell to Death (21 JANUARY 2013 )
Scientists annihilated lymphoma by depriving it of a favorite food:
HDL cholesterol. Researchers developed a new golden nanoparticle
that's a replica of natural HDL. Acting like a secret double agent,
the particle appears to the human lymphoma cell like natural HDL.
But when the cell engages it, the particle plugs up the cell and
blocks cholesterol from entering. The cell dies.
Click here to go at the top 2
http://www.sciencedaily.com/releases/2013/01/130120150031.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130120150031.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161917.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161917.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161915.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161915.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161915.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130121161917.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130120150031.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29 -
7/29/2019 GNIPST Bulletin 22.2
4/14
25-01-2013
Immune Cells Engineered in Lab to Resist HIV
In fection, Study Shows (22 JANUARY 2013 )
Researchers have found a novel way to engineer key cells of theimmune system so they remain resistant to infection with HIV, the
virus that causes AIDS. The new approach, a form of tailored gene
therapy, could ultimately replace drug treatment, in which patients
have to take multiple medications daily to keep the virus in check
and prevent the potentially fatal infections wrought by AIDS.
How Can Evolutionary Biology Explain Why We Get
Cancer? (22 JANUARY 2013 )
Over 500 billion cells in our bodies will be replaced daily, yet
natural selection has enabled us to develop defenses against thecellular mutations which could cause cancer. It is this relationship
between evolution and the bodys fight against cancer which is
explored in a new special issue of the Open Access journal
Evolutionary Applications. Low Vitamin D Levels Linked to High Risk of
Premenopausal Breast Cancer (24 JANUARY 2013 )Low serum vitamin D levels in the months preceding diagnosis may
predict a high risk of premenopausal breast cancer.
Click here to go at the top 3
http://www.sciencedaily.com/releases/2013/01/130122101903.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101903.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101454.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101454.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124183446.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124183446.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124183446.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101454.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101903.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130122101903.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29 -
7/29/2019 GNIPST Bulletin 22.2
5/14
25-01-2013
Stem Cell Therapy to Repair Damaged Knee
Cartilage (24 JANUARY 2013 )
Medical researchers are conducting the first clinical study in theU.S. of an innovative stem cell drug, Cartistem, to repair knee
cartilage damaged by aging, trauma or degenerative diseases such as
osteoarthritis.
HEALTH AWARENESS
Measles
Measles is a highly contagious, serious disease caused by a virus. In
1980, before widespread vaccination, measles caused an estimated
2.6 million deaths each year.
It remains one of the leading causes of death among young children
globally, despite the availability of a safe and effective vaccine. An
estimated 157 700 people died from measles in 2011 mostly
children under the age of five.
Measles is caused by a virus in the paramyxovirus family. Themeasles virus normally grows in the cells that line the back of the
throat and lungs. Measles is a human disease and is not known to
occur in animals.
Click here to go at the top 4
http://www.sciencedaily.com/releases/2013/01/130124163246.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124163246.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29http://www.sciencedaily.com/releases/2013/01/130124163246.htm?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine+%28ScienceDaily%3A+Health+%26+Medicine+News%29 -
7/29/2019 GNIPST Bulletin 22.2
6/14
25-01-2013
Accelerated immunization activities have had a major impact on
reducing measles deaths. Since 2000, more than one billion children
in high risk countries were vaccinated against the disease through
mass vaccination campaigns about 225 million of them in 2011.
Global measles deaths have decreased by 71% from 548,300 to 157
700.
Signs and symptoms
The first sign of measles is usually a high fever, which begins about10 to 12 days after exposure to the virus, and lasts four to seven days.
A runny nose, a cough, red and watery eyes, and small white spots
inside the cheeks can develop in the initial stage. After several days,
a rash erupts, usually on the face and upper neck. Over about three
days, the rash spreads, eventually reaching the hands and feet. The
rash lasts for five to six days, and then fades. On average, the rash
occurs 14 days after exposure to the virus (within a range of seven
to 18 days).
Severe measles is more likely among poorly nourished young
children, especially those with insufficient vitamin A, or whose
immune systems have been weakened by HIV/AIDS or otherdiseases.
Most measles-related deaths are caused by complications
associated with the disease. Complications are more common in
Click here to go at the top 5
-
7/29/2019 GNIPST Bulletin 22.2
7/14
25-01-2013
children under the age of five, or adults over the age of 20. The most
serious complications include blindness, encephalitis (an infection
that causes brain swelling), severe diarrhoea and related
dehydration, ear infections, or severe respiratory infections such as
pneumonia. As high as 10% of measles cases result in death among
populations with high levels of malnutrition and a lack of adequate
health care. Women infected while pregnant are also at risk of
severe complications and the pregnancy may end in miscarriage or
preterm delivery. People who recover from measles are immune forthe rest of their lives.
Who is at risk?
Unvaccinated young children are at highest risk of measles and its
complications, including death. Unvaccinated pregnant women are
also at risk. Any non-immune person (who has not been vaccinated or was vaccinated but did not develop immunity) can become
infected.
Measles is still common in many developing countries particularly
in parts of Africa and Asia. More than 20 million people are affected
by measles each year. The overwhelming majority (more than 95%)of measles deaths occur in countries with low per capita incomes
and weak health infrastructures.
Click here to go at the top 6
-
7/29/2019 GNIPST Bulletin 22.2
8/14
25-01-2013
Measles outbreaks can be particularly deadly in countries
experiencing or recovering from a natural disaster or conflict.
Damage to health infrastructure and health services interrupts
routine immunization, and overcrowding in residential camps
greatly increases the risk of infection.
Transmission
The highly contagious virus is spread by coughing and sneezing,
close personal contact or direct contact with infected nasal orthroat secretions.
The virus remains active and contagious in the air or on infected
surfaces for up to two hours. It can be transmitted by an infected
person from four days prior to the onset of the rash to four days after
the rash erupts.
Measles outbreaks can result in epidemics that cause many deaths,
especially among young, malnourished children. In countries where
measles has been largely eliminated, cases imported from other
countries remain an important source of infection.
Treatment
No specific antiviral treatment exists for measles virus.
Click here to go at the top 7
-
7/29/2019 GNIPST Bulletin 22.2
9/14
25-01-2013
Severe complications from measles can be avoided though
supportive care that ensures good nutrition, adequate fluid intake
and treatment of dehydration with WHO-recommended oral
rehydration solution. This solution replaces fluids and other
essential elements that are lost through diarrhoea or vomiting.
Antibiotics should be prescribed to treat eye and ear infections, and
pneumonia.
All children in developing countries diagnosed with measles should
receive two doses of vitamin A supplements, given 24 hours apart.
This treatment restores low vitamin A levels during measles that
occur even in well-nourished children and can help prevent eye
damage and blindness. Vitamin A supplements have been shown to
reduce the number of deaths from measles by 50%.
Prevention
Routine measles vaccination for children, combined with mass
immunization campaigns in countries with high case and death
rates, are key public health strategies to reduce global measles
deaths. The measles vaccine has been in use for over 40 years. It is
safe, effective and inexpensive. It costs less than one US dollar toimmunize a child against measles.
Click here to go at the top 8
-
7/29/2019 GNIPST Bulletin 22.2
10/14
25-01-2013
The measles vaccine is often incorporated with rubella and/or
mumps vaccines in countries where these illnesses are problems. It
is equally effective in the single or combined form.
In 2011, about 84% of the world's children received one dose of
measles vaccine by their first birthday through routine health
services up from 72% in 2000. Two doses of the vaccine are
recommended to ensure immunity and prevent outbreaks, as about
15% of vaccinated children fail to develop immunity from the first
dose.
DISEASE OUTBREAK NEWS
FORTHCOMING EVENTS
1st international conference on emerging trends in chemica
pharmaceutical sciences and First convention of ICCPDate: 28 Jun 2013 30 Jun 2013, Location: Jawaharlal Nehru Technologic
University, Anantapur campus, Anantapur, Andhra Pradesh.
DRUGS UPDATES
FDA approves Exjade to remove excess iron in
patients with genetic blood disorder
(23 JANUARY 2013 )
Click here to go at the top 9
http://www.publication4u.com/link.php?M=102715&N=9&L=2&F=Hhttp://www.publication4u.com/link.php?M=102715&N=9&L=2&F=Hhttp://www.publication4u.com/link.php?M=102715&N=9&L=2&F=H -
7/29/2019 GNIPST Bulletin 22.2
11/14
25-01-2013
The U.S. Food and Drug Administration expanded the approved
use of Exjade (deferasirox)to treat patients ages 10 years and older
who have chronic iron overload resulting from a genetic blood
disorder called non-transfusion-dependent thalassemia (NTDT).
CAMPUS NEWS
STUDENTS SECTION
WHO CAN ANS WER FIRS T ???
() Which toxin was also known as sausage
poison?
() Project 523 was established by Chinese army to
discover the new treatment strategy for which
disease?
A) Camptothecin B) Camptotheca acuminata
Click here to go at the top 10
mailto:[email protected]:[email protected]:[email protected]://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336478.htm -
7/29/2019 GNIPST Bulletin 22.2
12/14
25-01-2013
EDITORS NOTE
I am very happy to publish the 2 nd issue of 22 nd Volume of GNIPST
BULLETIN. It is my great pleasure to introduce you to the newly
launched facebook account GNIPST bulletin . You are cordially
invited to add this account to your friend list. The current issues will
also be directly available on facebook.
I would like to convey my thanks to all the GNIPST members and
the readers for their valuable comments, encouragement& supports.Special thanks to Dr. Prerona Saha for her advice; Mr. Soumya
Bhattacharya, for his contribution in students section .
It would be my great pleasure to receive the contributions,
suggestions & feedback from your desk for further upliftment of this
deliberation GNIPST BULLETIN.
ARCHIVE
The general body meeting of APTI, Bengal Branch has been
conducted at GNIPST on 15th June, 2012. The programme started
with a nice presentation by Dr. Pulok Kr. Mukherjee, School of
Natural Products, JU on the skill to write a good manuscript for
publication in impact journals. It was followed by nearly two hour
long discussion among more than thirty participants on different
Click here to go at the top 11
-
7/29/2019 GNIPST Bulletin 22.2
13/14
25-01-2013
aspects of pharmacy education. Five nonmember participants
applied for membership on that very day.
GNIPST is now approved by AICTE and affiliated to WBUT forconducting the two years post graduate course (M.Pharm) in
The approved number of seat is 18.
The number of seats in B.Pharm. has been increased from60 to 120.
2nd World Congress on Ga-68 (Generators and Novel Radiopharmaceut
Molecular Imaging (PET/CT), Targeted Radionuclide Therapy, and Dos(SWC-2013) : On the Way to Personalized Medicine
Dates 28 Feb 2013 02 Mar 2013
Location: Chandigarh, India.
AICTE has sanctioned a release of grant under Research
Promotion Scheme (RPS) during the financial year 2012-
13to GNIPST as per the details below:
a. Beneficiary Institution: Guru Nanak Institution of
Pharmaceutical Science & Technology.
b. Principal Investigator: Dr. LopamudraDutta.
c. Grant-in-aid sanctioned: Rs. 16,25000/- only
d. Approved duration: 3 years
e. Title of the project: Screening and identification of potential
medicinal plant of Purulia&Bankura districts of West Bengal with
Click here to go at the top 12
http://www.2ndworldcongress-ga-68.de/http://www.2ndworldcongress-ga-68.de/http://www.2ndworldcongress-ga-68.de/ -
7/29/2019 GNIPST Bulletin 22.2
14/14
25-01-2013
respect to diseases such as diabetes, rheumatism, Jaundice,
hypertension and developing biotechnological tools for enhancing
bioactive molecules in these plant.
Special classes on Communication Skills, G.D. and
Interview will commence from 3rd week of January 2013
for the students of this Institute. Interested students are
required to contact the undersigned for enrolment either
personally or by e-mail.
Dr. LopamudraDatta E-mail : [email protected]
Click here to go at the top 13
mailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]